Ulcerative colitis is a chronic inflammatory bowel disease that causes inflammation and ulcers in the innermost lining of the large intestine (colon) and rectum. It affects roughly 2 to 44 people per 100,000 each year depending on the region, and its incidence has been climbing steadily, particularly among children and young adults. Unlike some digestive conditions that come and go without lasting changes, ulcerative colitis involves ongoing immune-driven damage that requires long-term management.
How Ulcerative Colitis Affects the Colon
The inflammation in ulcerative colitis is restricted to the mucosa and submucosa, the two innermost layers of the colon wall. This is one of the key features that distinguishes it from Crohn’s disease, which can penetrate through all layers of the intestinal wall and appear anywhere in the digestive tract.
Ulcerative colitis almost always starts in the rectum and spreads upward in a continuous, unbroken pattern. There are no “skip areas” of healthy tissue between inflamed sections. During a colonoscopy, doctors typically see a loss of the normal blood vessel pattern in the colon lining, along with tissue that looks grainy, bleeds easily, and may have open ulcers. This continuous, symmetrical pattern of damage is what makes ulcerative colitis recognizable on examination.
Common Symptoms
The hallmark symptoms are bloody diarrhea, urgent bowel movements, and abdominal cramping. Many people experience a constant feeling that they need to use the bathroom, even right after going. During flares, you might have 10 or more bowel movements a day, often with visible blood or mucus. Fatigue is extremely common and can be one of the most disabling aspects of the disease, partly from inflammation itself and partly from blood loss and poor nutrient absorption.
The severity varies widely. Some people have mild symptoms limited to the rectum, while others develop inflammation across the entire colon with fever, weight loss, and severe pain. The disease follows a relapsing-remitting course, meaning periods of active symptoms (flares) alternate with stretches of relative quiet (remission).
What Causes It
No single cause has been identified. Ulcerative colitis develops from a combination of genetic susceptibility, immune system dysfunction, and environmental triggers. The immune system mistakenly attacks the colon lining, and once this process starts, it tends to persist.
On the genetic side, certain immune-related genes play a significant role. People who carry a specific variant called HLA-DRB1*0103 are more likely to develop severe, extensive disease requiring hospitalization and surgery. First-degree relatives of someone with ulcerative colitis also have a higher risk of developing the condition themselves.
Environmental factors matter too, sometimes in unexpected ways. Smoking is actually protective against ulcerative colitis, and quitting smoking can trigger flares. This is the opposite of Crohn’s disease, where smoking makes things worse. The gut microbiome also appears central to the disease. The “microflora hypothesis” suggests that normal immune development depends on a healthy community of gut bacteria, and disruption of that community can set the stage for the kind of immune dysregulation seen in ulcerative colitis.
How It’s Diagnosed
Colonoscopy with tissue biopsies is the gold standard for diagnosing ulcerative colitis. During the procedure, a gastroenterologist can directly see the pattern of inflammation, take small tissue samples, and confirm the diagnosis under a microscope. The continuous pattern starting from the rectum is a key diagnostic clue.
Blood tests and stool tests help support the diagnosis and rule out infections. A stool marker called fecal calprotectin can help distinguish ulcerative colitis from irritable bowel syndrome (IBS), which causes similar symptoms but doesn’t involve visible inflammation. Elevated calprotectin suggests true intestinal inflammation rather than a functional gut disorder, though it isn’t specific enough to confirm the diagnosis on its own.
Effects Beyond the Gut
Ulcerative colitis isn’t just a colon disease. The same immune dysfunction that drives gut inflammation can affect joints, skin, eyes, and the liver.
- Joints: The most common non-gut symptom. This ranges from general joint aching to full inflammatory arthritis with swelling and warmth. A smaller number of people develop conditions affecting the spine and hips, like ankylosing spondylitis.
- Skin: Rashes, painful skin lesions, and ulcers can appear during flares or independently. Some ulcerative colitis medications also thin the skin or worsen acne.
- Eyes: Inflammation of the middle layer of the eye (uveitis) or the iris can cause pain, redness, and blurred vision, usually in one eye. These episodes often coincide with active gut inflammation.
- Liver: Primary sclerosing cholangitis (PSC) is a serious liver condition linked to ulcerative colitis. It causes inflammation and scarring of the bile ducts and can progress to cirrhosis, liver failure, or cancer. Autoimmune hepatitis, where the immune system attacks the liver directly, is another possibility.
Treatment Options
Treatment focuses on two goals: stopping active flares (induction) and preventing them from coming back (maintenance). The approach depends on how severe the disease is and how much of the colon is involved.
For mild to moderate disease, anti-inflammatory drugs that target the colon lining directly are typically the first step. These reduce inflammation locally with fewer body-wide side effects. Corticosteroids are used for more intense flares but aren’t suitable for long-term use because of side effects like bone thinning and weight gain.
For moderate to severe disease that doesn’t respond to standard anti-inflammatory treatment, biologic medications have transformed care over the past decade. Some biologics work by blocking a protein called TNF-alpha that drives inflammation, neutralizing it before it can signal immune cells to attack the colon. Others work by preventing certain immune cells from migrating into the gut in the first place. Newer oral medications that interrupt inflammatory signaling pathways inside cells have added another option for people who don’t respond to biologics. Immune-modifying drugs that broadly dial down immune activity are also used, sometimes in combination with biologics.
Finding the right medication often takes trial and adjustment. Some people respond well to their first treatment, while others cycle through several options before achieving stable remission. Genetic factors can even influence treatment response: carrying certain gene variants can double the risk of developing antibodies against biologic medications, reducing their effectiveness.
When Surgery Becomes Necessary
Between 20 and 30 percent of people with ulcerative colitis eventually need surgery. The most common reasons are disease that no longer responds to medications, precancerous changes found during surveillance, or colon cancer itself. Emergency surgery may be needed for severe flares that cause life-threatening complications like toxic megacolon (dangerous dilation of the colon) or uncontrollable bleeding.
The preferred surgical approach removes the entire colon and rectum, then creates an internal pouch from the small intestine that connects to the anus. This “J-pouch” procedure allows most people to have bowel movements without a permanent external bag, though the frequency of bowel movements is usually higher than before, typically four to eight times daily. For some people, surgery brings a dramatic improvement in quality of life after years of poorly controlled disease.
Colorectal Cancer Risk and Screening
Long-standing ulcerative colitis increases the risk of colorectal cancer. The risk grows with disease duration, the extent of colon involvement, and the degree of ongoing inflammation. Most guidelines recommend a screening colonoscopy about 8 years after symptoms first appeared to evaluate how much of the colon is affected and establish a surveillance plan.
After that initial screen, follow-up colonoscopies are recommended every 1 to 3 years for most people, with annual screening for those at higher risk. Risk factors that warrant more frequent screening include a liver condition called PSC, a history of precancerous changes, active ongoing inflammation, a family history of colorectal cancer, and structural changes in the colon like strictures. People with lower risk profiles and consistently normal surveillance results can sometimes extend intervals to every 3 to 5 years.
Diet and Daily Management
No diet has been consistently shown to prevent flares in ulcerative colitis. That said, the American Gastroenterological Association recommends a Mediterranean-style diet for all people with inflammatory bowel disease: rich in fresh fruits and vegetables, healthy fats like olive oil, complex carbohydrates, and lean proteins, while limiting ultra-processed foods, added sugar, and excess salt. This pattern supports overall health and may help reduce low-grade inflammation.
There is some evidence that reducing red and processed meat may lower the frequency of ulcerative colitis flares specifically, though the evidence isn’t strong enough to make it a firm rule. During active flares, many people find that certain foods worsen symptoms, and a temporary shift toward softer, lower-fiber foods can help with comfort. Raw fruits and vegetables can be harder to tolerate during flares, but cooking them to a soft consistency often makes them manageable. The key is paying attention to your own patterns rather than following a rigid elimination diet, since triggers vary widely from person to person.
Stress doesn’t cause ulcerative colitis, but it can trigger or worsen flares. Regular exercise, adequate sleep, and stress management aren’t substitutes for medical treatment, but they play a real supporting role in keeping the disease quieter over time.